Furthermore, we showed that CEP-1347 activated p53 and inhibited the growth of p53 wild-type cancer cells not only when used alone, but more efficiently when used in combination with a MDM2 inhibitor [31]; however, the effects of combining CEP-1347 with IR, which is commonly employed for the treatment of GBM and MM, remain unknown. Here, TP53 is linked to cancer.